PIK3CD and neoplasm: Further understanding of the PI3K signaling and crosstalk with related pathways, its role in activating or suppressing the tumor-infiltrating lymphocytes, and better patient stratification and selection strategies will be essential patient response in the clinical development of PI3K inhibitors and their possible combination approach with immunotherapies.